There are currently 23 ongoing clinical trials involving Acromegaly
Of the 23 trials,7 trials are in Phase II
Furthermore, 7 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Acromegaly, a Hormonal Disorder. The highest number of ongoing clinical trials involving Acromegaly is in Europe. North America, and Asia-Pacific are among some of the other prominent regions involved in Acromegaly-related drug trials.
Camurus AB: The leading ongoing Acromegaly related clinical trials sponsor
Camurus AB is the top sponsor for Acromegaly-related ongoing clinical trials.
Sapienza University of Rome, Crinetics Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc are a few other notable sponsors involving Acromegaly. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Acromegaly
Octreotide Acetate (Sandostatin), Lanreotide acetate (Somatuline Depot/ Somatuline/ Lanreoscan), and Pegvisomant (Somavert) are among the key marketed drugs involving Acromegaly.
Octreotide Acetate (Sandostatin) is the acetate salt of a cyclic octapeptide acts as anti-neoplastic agent. It functions via Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Agonist; Somatostatin Receptor Type 5 (SSTR5) Agonist mechanism of action. It is formulated as solution for intravenous or subcutaneous route of administration. Sandostatin is marketed for the treatment of Acromegaly and several other indications including Diarrhea, Hypoglycemia, Zollinger-Ellison Syndrome (Gastrinoma), Gigantism, HIV Associated Diarrhea, Carcinoid Syndrome (Malignant Carcinoid Syndrome), Carcinoid Tumor, Esophageal Varices, Gastrointestinal Carcinoid Tumor, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). It was first approved in 1987 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Novartis AG and its Subsidiaries, and GSK Russia.
Lanreotide acetate (Somatuline Depot/ Somatuline/ Lanreoscan) is a synthetic octapeptide analogue of somatostatin, an endogenous peptide, acts as antineoplastic agents. It functions via Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Agonist; Somatostatin Receptor Type 5 (SSTR5) Agonist mechanism of action. It is formulated as solution, powder for solution and powder for suspension for intramuscular and subcutaneous routes of administration. Lanreotide is indicated for the treatment of acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, Lanreotide acetate is also used to treat several other indications including Adenomas, Neuroendocrine Tumors, Carcinoid Syndrome (Malignant Carcinoid Syndrome), Carcinoid Tumor, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). Lanreotide acetate was first approved in 1994 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Ipsen SA and subsidiaries, and several other prominent companies including Teijin Pharma Ltd, and Sanofi-Aventis de Mexico SA de CV.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer